

Q3 2026 Earnings Presentation

November 4, 2026

Forward-looking statements and non-GAAP information


This presentation contains forward-looking statements, including, but not limited to our statements related to our plans, objectives, and expectations (financial and otherwise), including with respect to our 2026 financial and operating results; our assumptions for future revenue growth; the commercialization, adoption and reimbursement of our TrueMRD platform and our Prosigna test; the timing for broader availability of Decipher Prostate for use in the metastatic population; expected completion of our IVD development and manufacturing work for our Decipher PCR and Prosigna NGS tests; enrollment in our studies and trials; our strategic focuses for the business; and our intentions with respect to our tests and products, for use in diagnosing and treating diseases, in and outside of the United States. Forward-looking statements can be identified by words such as: “appears,” “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,” “could,” “would,” “will,” “enable,” “positioned,” “offers,” “designed,” “look forward,” “vision,” “strategic,” “on track,” “progress,” “outlook,” “guidance,” “forecast,” “target,” “goal” and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions, and include, but are not limited to: our ability to launch, commercialize and receive reimbursement for our products; our ability to execute on our business strategies relating to the C2i Genomics and Convergent Genomics acquisitions, integration of the businesses and the realization of expected benefits and synergies; our ability to demonstrate the validity and utility of our genomic tests and biopharma and other offerings; our ability to continue executing on our business plan; our ability to continue to scale our global operations and enhance our internal control environment; the impact of the war in Ukraine, and other regional conflicts, on European economies; the impact of foreign currency fluctuations, volatile interest rates, inflation, the impact of tariffs, and the impact of legislation and policies enacted by the current U.S. administration; turmoil in the global banking and finance system; the ongoing conflict in the Middle East and the performance and utility of our tests in the clinical environment. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on February 26, 2026, as well as in other documents that we may file from time to time with the Securities and Exchange Commission. Copies of these documents, when available, may be found in the Investors section of our website at investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

This presentation also contains information gathered from market research, estimates and other statistical data made by independent parties and by us relating to addressable market size and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this presentation contains certain non-GAAP results including non-GAAP gross margin, non-GAAP operating expenses, adjusted EBITDA, adjusted EBITDA as a percentage of revenue, non-GAAP net income, non-GAAP earnings per share (EPS) and non-GAAP weighted average shares outstanding (WASO). These non-GAAP financial measures are not meant to be considered superior to or a substitute for financial measures calculated in accordance with GAAP, and investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool. We use non-GAAP financial measures to internally evaluate and analyze financial results. We believe these non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance, and enable comparison of our financial results with other public companies, many of which present similar non-GAAP financial measures. However, the non-GAAP financial measures we present may be different from those used by other companies, including similarly titled measures.

We compute these non-GAAP measures by adjusting the applicable GAAP measure to remove the impact of certain recurring and non-recurring charges and gains and to adjust for the impact of income tax items related to such adjustments to our GAAP financial statements. In particular, we exclude amortization of acquired intangible assets, acquisition-related expenses, impairment charges associated with the nCounter license and other biopharmaceutical services related to HalioDx intangible assets, stock-based compensation and certain costs related to restructuring from certain of our non-GAAP measures. Beginning in the second quarter of 2024, we changed our non-GAAP policy to exclude all stock-based compensation to align with our peers and we have also excluded all stock-based compensation from all of our prior-period non-GAAP financial measures, as well as depreciation and income tax items from our adjusted EBITDA and adjusted EBITDA as a percentage of revenue. Management has excluded the effects of these items in non-GAAP financial measures to help investors gain a better understanding of our core operating results and future prospects, consistent with how management measures and forecasts our performance, especially when comparing such results to previous periods or forecasts. We encourage investors to carefully consider our results under GAAP, together with our supplemental non-GAAP information and the reconciliation between these presentations. Reconciliations between our GAAP results and non-GAAP financial measures are presented in the Appendix.

© 2026 Veracyte, Inc. The trademarks mentioned herein are the property of Veracyte (for a non-exhaustive list, see www.veracyte.com/trademarks) or their respective owners.


Solid Q3 results with exciting portfolio momentum



- **Strong profitability and cash generation**
- **Afirma exceeded expectations;**
  Decipher Prostate volume was lower than expected
- **Advanced our breast and bladder strategies**
  following recent new product launches
- **Strengthened our urology portfolio**
  through the acquisition of Convergent Genomics
- **Advanced market access strategies**
  in breast, prostate and bladder cancer

Decipher

Growing Decipher Prostate



Volume figures are rounded for reporting purposes. Growth rates are calculated from actual (unrounded) figures and may differ slightly.

© 2026 Veracyte, Inc. All rights reserved.

Decipher

Investing in our urology commercial channel to support broader adoption and deeper utilization

Increasing the urology team by ~30% in 2027 across field representatives, medical science liaisons, and sales leadership

Expanding efforts to generate and articulate new predictive and prognostic claims

Adding bioinformatics capabilities to capture real-world evidence benefit and support ongoing clinical study analysis

Investments expected to drive growth across our expanding urology portfolio

- Decipher Prostate
- Decipher Bladder
- TrueMRD MIBC
- UroAmp

Decipher

Advancing evidence-based catalysts across the prostate cancer risk spectrum

New predictive evidence

INTERMEDIATE-RISK
Predicting benefit from adding short-term hormone therapy to radiation

HIGH AND VERY-HIGH RISK
Predicting benefit from adding abiraterone to ADT

METASTATIC
Predicting benefit of adding chemotherapy to doublet therapy

Key phase III trial readouts

LOW-RISK
GENI-AIRSPACE,
G-MAJOR

INTERMEDIATE-RISK
GUIDANCE

HIGH-RISK AND VERY-HIGH RISK
PREDICT-RT


New insights added to our offering

MOLECULAR FEATURES REPORT
Advancing our molecular features report with new clinically validated signatures

DPAI STRATEGY
Combining digital pathology and molecular insights

Afirma

Growing Afirma



- **Growth driven by deeper utilization among existing physicians and continued share gains**
- **Strongest sequential Q3 step up in volume since 2020**
- **Reduced no-result rate, contributed ~300 bps to YoY volume growth in Q3**

Volume figures are rounded for reporting purposes. Growth rates are calculated from actual (unrounded) figures and may differ slightly.

© 2026 Veracyte, Inc. All rights reserved.

Prosigna®

Prosigna is a well-validated prognostic and predictive test for breast cancer

157 publications to date

and >1,200 publications featuring the PAM50 classifier that Prosigna was built on

Included in NCCN guidelines

for patients with 0-3 positive lymph nodes based on strong prognostic performance

OPTIMA data could expand Prosigna's role in guidelines

for predicting chemotherapy benefit in higher-risk patients

Prosigna®

Further evidence enables serving more patients with early-stage breast cancer

Health-economic analysis showed Prosigna-guided treatment can deliver meaningful cost savings for the UK health system

Upcoming quality-of-life analyses for patients within the OPTIMA trial will add evidence on clinical utility and patient impact

20+ studies ongoing or pending publication that will strengthen our prospective and retrospective evidence across subgroups

~225,000 patients diagnosed annually in the U.S. with ER+ / HER2- breast cancer[1] may benefit from Prosigna testing

1. Company estimates based on breastcancer.org estimate of ~317,000 women in the US that were diagnosed with breast cancer in 2025 & komen.org estimate that about 70% to 80% of newly diagnosed breast cancers are HR+

Prosigna®

Launch of the Prosigna test is tracking to plan, with encouraging early demand

Driving broader adoption

with ~15 medical oncology representatives by year-end

Progressing reimbursement

Secured Medicare reimbursement for eligible patients diagnosed with early-stage HR+ breast cancer

Strong momentum internationally

Product revenue grew +40% YoY in Q3, reflecting strong adoption of Prosigna IVD

Bladder

Comprehensive bladder portfolio leverages tissue, urine, and blood

Diagnosis	Prognosis	Treatment Guidance and Monitoring		Post-Treatment Surveillance
~85,000 patients diagnosed with bladder cancer each year in the U.S.[1]	**NMIBC[1] ~65,000**	**Decipher Bladder** *Covered by Medicare* Risk stratification	**UroAmp** *First planned indication* Informing post-induction maintenance decision	**UroAmp** *Planned indication* Monitoring response to therapy	**UroAmp** *Planned indication* Post-treatment surveillance
	MIBC[2] ~20,000	**Decipher Bladder** *Covered by Medicare* Risk stratification			**TrueMRD for MIBC** *Covered by Medicare* Recurrence monitoring following radical cystectomy

1. National Cancer Institute, Surveillance, Epidemiology and End Results (SEER) Program. *SEER Cancer Stat Facts: Common Cancer Sites.* https://seer.cancer.gov/statfacts/html/common.html
2. NMIBC – non-muscle invasive bladder cancer; Attanasio G, et al. *Histological and immunohistochemical approaches to molecular subtyping of muscle-invasive bladder cancer.* Frontiers in Oncology. 2025.
3. MIBC = muscle-invasive bladder cancer

Bladder

UroAmp adds a differentiated urine-based DNA platform to our urology portfolio

Strong and growing evidence base

9 publications and >40 abstracts and posters to date

4 additional abstracts were accepted for SUO


INSITE trial data supporting the first application will be presented at SUO and was accepted for peer-reviewed publication

On track to launch the first application

First application: informing the post-induction maintenance decision

Targeting a late 2028 launch with Medicare reimbursement; additional applications to follow


Years of growth reflects the strength of our portfolio



Topline growth driven by testing revenue


Total Revenue (M)[1]

Q3



Testing Revenue (M)[1]

Q3



Testing Volume (K)

Q3



Testing ASP of $2,960[2]
+1% YoY


Normalized ASP of $2,900[3]
+2% YoY, adjusted for prior period collections

1. Testing revenue includes cytology revenue of $2.3M in the third quarter of 2026 and $2.5M in the third quarter of 2025
2. ASP calculated as testing revenue of $146.4M divided by testing volume of approximately 49,500
3. ASP calculated as testing revenue $146.4M excluding ~$2.5M of prior period collections divided by testing volume of approximately 49,500

Delivered strong net income and adjusted EBITDA


GAAP Net Income (M)

Q3




Adjusted EBITDA Margin

Q3



Cash and Short-term Investments (M)[1]

End of Quarter




Generated $40.3 million in cash from operations in Q3


1. Ending balance of cash, cash equivalents and short-term investments, excluding restricted cash
2. Ending balance after an approximately $150 million cash payment for the acquisition of Convergent Genomics

Updated outlook for 2026

Revenue (M)[1]



Testing Revenue (M)[1]



Minimal contribution from new tests

Adjusted EBITDA Margin[1,3]



>26% adjusted EBITDA margin

1. Guidance provided as of November 4, 2026
2. The company is unable to provide a quantitative reconciliation of expected adjusted EBITDA as a percentage of revenue to the most directly comparable forward-looking GAAP measure, without unreasonable effort, because of the inherent difficulty in accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliations that have not yet occurred, that are dependent on various factors, are out of the company's control, or that cannot be reasonably predicted. Such adjustments include, but are not limited to, acquisition related expenses and other adjustments. Any associated estimate of these items and their impact on GAAP performance for the guidance period could vary materially. For more information on the non-GAAP financial measures, please refer to the section titled "Forward-looking statements and non-GAAP information" at the beginning of this presentation

© 2026 Veracyte, Inc. All rights reserved.

Our vision is to **transform cancer care for patients** all over the world




veracyte®

Reconciliation of Non-GAAP Gross Profit and Gross Margin

(Unaudited)
(In thousands of dollars)

Three Months Ended	Jun 30, 2025	Sep 30, 2025	Dec 31, 2025	Mar 31, 2026	Jun 30, 2026	Sep 30, 2026
GAAP cost of testing revenue	$ 32,407	$ 33,777	$ 33,118	$ 33,306	$ 36,309	$ 38,477
Stock-based compensation expense	(542)	(555)	(616)	(1,099)	(959)	(994)
Acquisition related expenses (1)	-	-	-	-	-	(131)
Other adjustments (2)	-	-	-	(300)	(338)	(316)
Non-GAAP cost of testing revenue	**$ 31,865**	**$ 33,222**	**$ 32,502**	**$ 31,907**	**$ 35,012**	**$ 37,036**
GAAP cost of product revenue	1,749	3,015	2,621	1,891	2,515	2,766
Stock-based compensation expense	(1)	-	-	-	(1)	(1)
Acquisition related expenses (1)	-	-	-	-	-	-
Other adjustments (2)	(32)	(1,418)	(281)	11	-	-
Non-GAAP cost of product revenue	**$ 1,716**	**$ 1,597**	**$ 2,340**	**$ 1,902**	**$ 2,514**	**$ 2,765**
GAAP cost of biopharmaceutical and other revenue	$ 3,572	$ 1,091	$ 217	$ 8	$ 207	$ 142
Stock-based compensation expense	(65)	15	(2)	-	-	-
Acquisition related expenses (1)	-	-	-	-	-	-
Other adjustments (2)	-	-	-	-	-	-
Non-GAAP cost of biopharmaceutical and other revenue	**$ 3,507**	**$ 1,106**	**$ 215**	**$ 8**	**$ 207**	**$ 142**
GAAP Gross Profit	$ 89,769	$ 91,282	$ 101,973	$ 101,159	$ 108,549	$ 107,104
GAAP Gross Margin	69.0 %	69.2 %	72.5 %	72.7 %	72.2 %	70.6 %
Amortization of intangible assets	2,667	2,707	2,707	2,707	2,741	3,265
Stock-based compensation expense	608	540	618	1,099	960	995
Acquisition related expenses (1)	-	-	-	-	-	131
Other adjustments (2)	32	1,418	281	289	338	316
Non-GAAP Gross Profit	**$ 93,076**	**$ 95,947**	**$ 105,579**	**$ 105,254**	**$ 112,588**	**$ 111,811**
Non-GAAP Gross Margin	**71.5 %**	**72.8 %**	**75.1 %**	**75.7 %**	**74.9 %**	**73.7 %**

1. Includes transaction-related expenses. For the three months ended September 30, 2026, adjustments consist primarily of transaction-related expenses associated with acquisition activities ($0.1M).
2. For the three months ended September 30, 2026, and the three months ended June 30, 2026, adjustments include the impact of Non-GAAP adjustments on IT/Facilities allocations ($0.3M). For the three months ended March 31, 2026, adjustments include the impact of Non-GAAP adjustments on IT/Facilities allocations ($0.3M), partially offset by expense related to the restructuring of Veracyte SAS. For the three months ended December 31, 2025, adjustments include expenses related to the restructuring of Veracyte SAS ($0.3M). For the three months ended September 30, 2025, and the three months ended June 30, 2025, adjustments include expenses related to the restructuring and liquidation proceedings of Veracyte SAS.
3. Some figures rounded for reporting purposes. Summed quarters may differ slightly from year-to-date figures presented due to rounding.

Reconciliation of Non-GAAP Operating Expenses

(Unaudited)
(In thousands of dollars)

Three Months Ended	Jun 30, 2025	Sep 30, 2025	Dec 31, 2025	Mar 31, 2026	Jun 30, 2026	Sep 30, 2026
GAAP research and development	$ 16,264	$ 15,981	$ 20,849	$ 27,098	$ 29,442	$ 32,159
Stock-based compensation expense	(2,008)	(1,949)	(1,895)	(2,680)	(2,917)	(2,742)
Acquisition related expenses (1)	-	-	-	-	-	(1)
Other adjustments (2)	-	-	-	(277)	(199)	(176)
Non-GAAP research and development	**$ 14,256**	**$ 14,032**	**$ 18,954**	**$ 24,141**	**$ 26,326**	**$ 29,240**
GAAP sales and marketing	$ 25,316	$ 24,455	$ 25,940	$ 27,156	$ 28,263	$ 28,652
Stock-based compensation expense	(2,198)	(2,102)	(2,060)	(2,399)	(2,706)	(2,734)
Acquisition related expenses (1)	-	-	-	-	-	-
Other adjustments (2)	-	-	-	(31)	(48)	(45)
Non-GAAP sales and marketing	**$ 23,118**	**$ 22,353**	**$ 23,880**	**$ 24,726**	**$ 25,509**	**$ 25,873**
GAAP general and administrative	$ 32,331	$ 27,278	$ 17,367	$ 23,680	$ 27,443	$ 29,302
Stock-based compensation expense	(6,171)	(6,166)	(6,328)	(6,583)	(7,503)	(7,488)
Acquisition related expenses (1)	925	(166)	12,564	367	319	(1,321)
Other adjustments (2)	(4,144)	1,308	(1,309)	(1,695)	(2,127)	(2,694)
Non-GAAP general and administrative	**$ 22,941**	**$ 22,254**	**$ 22,294**	**$ 15,769**	**$ 18,132**	**$ 17,799**
GAAP total operating expenses	**$ 95,037**	**$ 68,336**	**$ 64,778**	**$ 78,513**	**$ 85,569**	**$ 90,535**
Amortization of intangible assets	(621)	(622)	(622)	(579)	(421)	(422)
Stock-based compensation expense	(10,377)	(10,217)	(10,283)	(11,662)	(13,126)	(12,964)
Acquisition related expenses (1)	925	(166)	12,564	367	319	(1,322)
Other adjustments (2)	(24,649)	1,308	(1,309)	(2,003)	(2,374)	(2,915)
Non-GAAP total operating expenses	**$ 60,315**	**$ 58,639**	**$ 65,128**	**$ 64,636**	**$ 69,967**	**$ 72,912**

1. Includes transaction-related expenses as well as post-combination compensation expenses. For the three months ended September 30, 2026, adjustments consist of transaction-related expenses associated with the acquisition of Convergent Genomics, Inc. ($1.7M) partially offset with contingent consideration related to the NanoString Technologies, Inc. ("NanoString") transaction ($0.4M). For the three months ended June 30, 2026, adjustments consist primarily of transaction-related expenses associated with contingent consideration related to the NanoString transaction ($0.3M). For the three months ended March 31, 2026, adjustments consist primarily of transaction-related expenses associated with contingent consideration related to the NanoString transaction ($0.4M). For the three months ended December 31, 2025, adjustments consist primarily of transaction-related expenses associated with contingent consideration related to the NanoString transaction ($0.7M) and contingent consideration associated with the C2i Genomics acquisition ($11.9M). For the three months ended September 30, 2025, adjustments consist primarily of transaction-related expenses associated with contingent consideration related to the NanoString transaction and contingent consideration associated with the C2i Genomics acquisition. For the three months ended June 30, 2025, adjustments consist primarily of transaction-related expenses associated with contingent consideration related to the NanoString transaction ($1.0M) partially offset by contingent consideration associated with the acquisition of C2i Genomics ($0.1M).
2. For the three months ended September 30, 2026, adjustments consist primarily of expenses related to legal proceedings ($3.2M), partially offset by the impact of Non-GAAP adjustments on IT/Facilities allocations ($0.3M). For the three months ended June 30, 2026, adjustments consist primarily of expenses related to the assessment of licensing and strategic investments ($1.3M), expenses related to legal proceedings ($1.0M), and expenses related to the liquidation proceedings of Veracyte SAS ($0.3M), partially offset by the impact of Non-GAAP adjustments on IT/Facilities allocations ($0.3M). For the three months ended March 31, 2026, adjustments consist primarily of expenses related to the assessment of licensing and strategic investments ($1.7M) and expenses related to legal proceedings ($0.6M), partially offset by the impact of Non-GAAP adjustments on IT/Facilities allocations ($0.3M). For the three months ended December 31, 2025, adjustments primarily include expenses related to the restructuring and liquidation proceedings of Veracyte SAS ($1.1M) and other legal proceedings ($0.2M). For the three months ended September 30, 2025, adjustments primarily include a vendor legal settlement ($2.8M) partially offset by expenses related to the restructuring and liquidation proceedings of Veracyte SAS ($1.0M) and other legal proceedings ($0.5M). For the three months ended June 30, 2025, adjustments primarily include expenses related to Veracyte SAS impairment loss ($20.5M) and expenses related to the restructuring and liquidation proceedings of Veracyte SAS ($4.2M).
3. Some figures rounded for reporting purposes. Summed quarters may differ slightly from year-to-date figures presented due to rounding.

Reconciliation of Adjusted EBITDA

(Unaudited)
(In thousands of dollars)

Three Months Ended	Jun 30, 2025	Sep 30, 2025	Dec 31, 2025	Mar 31, 2026	Jun 30, 2026	Sep 30, 2026
GAAP Net Income (Loss)	$ (980)	$ 19,137	$ 41,149	$ 28,707	$ 25,490	$ 31,503
GAAP Net Income (Loss) as a % of Revenue	(0.8 %)	14.5 %	29.3 %	20.6 %	17.0 %	20.8 %
Amortization of intangible assets	3,288	3,329	3,329	3,286	3,163	3,687
Depreciation expense	2,201	1,938	1,968	2,144	1,676	2,293
Stock-based compensation expense	10,985	10,757	10,901	12,761	14,086	13,959
Acquisition related expenses (1)	(925)	166	(12,564)	(367)	(319)	1,453
Other expense (income), net (2)	(3,170)	(3,484)	(3,546)	(3,478)	(3,884)	(4,503)
Other adjustments (3)	22,147	8,138	1,590	(1,520)	2,712	3,231
Income tax expense (benefit)	2,230	(248)	(515)	1,267	1,033	(10,381)
Adjusted EBITDA	**$ 35,776**	**$ 39,733**	**$ 42,312**	**$ 42,800**	**$ 43,957**	**$ 41,242**
Adjusted EBITDA as a % of Revenue	**27.5 %**	**30.1 %**	**30.1 %**	**30.8 %**	**29.2 %**	**27.2 %**

1. Includes transaction-related expenses as well as post-combination compensation expenses. For the three months ended September 30, 2026, adjustments consist primarily of transaction-related expenses associated with the acquisition activities ($1.9 million), partially offset by contingent consideration related to the NanoString transaction ($0.4 million). For the three months ended June 30, 2026, adjustments consist primarily of transaction-related expenses associated with contingent consideration related to the NanoString Technologies, Inc. ("NanoString") transaction ($0.3M). For the three months ended March 31, 2026, adjustments consist primarily of transaction-related expenses associated with contingent consideration related to the NanoString transaction ($0.4M). For the three months ended December 31, 2025, adjustments consist primarily of transaction-related expenses associated with contingent consideration related to NanoString ($0.7M) and contingent consideration associated with the acquisition of C2i Genomics ($11.9M). For the three months ended September 30, 2025, adjustments consist primarily of transaction-related expenses associated with contingent consideration related to NanoString and contingent consideration associated with the acquisition of C2i Genomics. For the three months ended June 30, 2025, adjustments consist primarily of transaction-related expenses associated with contingent consideration related to NanoString ($1.0M) partially offset by contingent consideration associated with the acquisition of C2i Genomics ($0.1M).
2. Includes interest income and income related to research tax credits.
3. For the three months ended September 30, 2026, adjustments consist primarily of expenses related to legal proceedings ($3.2M). For the three months ended June 30, 2026, adjustments consist primarily of expenses related to the assessment of licensing and strategic investments ($1.3M), expenses related to legal proceedings ($1.0M), and expenses related to the liquidation proceedings of Veracyte SAS ($0.3M). For the three months ended March 31, 2026, adjustments primarily include impacts from the restructuring and liquidation proceedings of Veracyte SAS ($4.2M), partially offset by expenses related to the assessment of licensing and strategic investments ($1.7M), other legal proceedings ($0.6M) and losses related to asset disposition ($0.4M). For the three months ended December 31, 2025, adjustments primarily include expenses related to the restructuring and liquidation proceedings of Veracyte SAS ($1.4M) and other legal proceedings ($0.2M). For the three months ended September 30, 2025, adjustments primarily include expenses related to the exclusion of unrealized loss related to Veracyte SAS deconsolidation ($6.7M), the exclusion of unrealized loss associated with foreign exchange impact on stock-based compensation and intercompany loans ($1.3M), the restructuring and liquidation proceedings of Veracyte SAS ($2.4M), and other legal proceedings ($0.5M), partially offset by vendor legal settlement ($2.8M). For the three months ended June 30, 2025, adjustments primarily include expenses related to Veracyte SAS impairment loss ($20.5M) and the restructuring and liquidation proceedings of Veracyte SAS ($4.2M), partially offset by the exclusion of unrealized gains associated with foreign exchange impacts on stock-based compensation and intercompany loans ($2.5M).
4. Some figures rounded for reporting purposes. Summed quarters may differ slightly from year-to-date figures presented due to rounding.

Reconciliation of Adjusted EBITDA

(Unaudited)
(In thousands of dollars)

Twelve Months Ended	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025
GAAP Net Income (Loss)	$ (75,563)	$ (36,560)	$ (74,404)	$ 24,138	$ 66,353
GAAP Net Income (Loss) as a % of Revenue	(34.4 %)	(12.3 %)	(20.6 %)	5.4 %	12.8 %
Amortization of intangible assets	15,981	21,354	20,570	14,849	13,153
Depreciation expense	3,612	4,572	6,618	8,610	8,262
Stock-based compensation expense	22,968	27,456	33,489	36,249	43,601
Acquisition related expenses (1)	49,115	8,242	993	6,631	(11,971)
Other expense (income), net (2)	(1,077)	(4,280)	(7,922)	(11,647)	(13,176)
Other adjustments (3)	-	3,832	68,283	11,450	34,466
Income tax expense (benefit)	(6,086)	133	(2,208)	1,606	1,848
Adjusted EBITDA	**$ 8,950**	**$ 24,749**	**$ 45,419**	**$ 91,886**	**$ 142,536**
Adjusted EBITDA as a % of Revenue	**4.1 %**	**8.3 %**	**12.6 %**	**20.6 %**	**27.6 %**

1. Includes transaction-related expenses as well as post-combination compensation expenses. For the twelve months ended December 31, 2025, adjustments consist primarily of transaction-related expenses associated with the acquisition of C2i Genomics ($10.3M) and the NanoString contingent consideration ($1.7M). For the twelve months ended December 31, 2024, adjustments consist primarily of transaction-related expenses associated with the acquisition of C2i Genomics. For the twelve months ended December 31, 2023, adjustments consist primarily of remeasurement of contingent consideration related to our adoption of a multi-platform IVD strategy, post-combination compensation expenses associated with the acquisition of HalioDx, and transaction related expenses associated with the acquisition of C2i Genomics. For the twelve months ended December 31, 2022, adjustments consist primarily of post-combination compensation expenses associated with the acquisition of HalioDx. For the twelve months ended December 31, 2021, adjustments consist primarily of transaction-related expenses associated with the acquisition of Decipher Biosciences ($35.7M) and post-combination compensation expenses and other transaction-related expenses associated with the acquisition of HalioDx ($13.4M).
2. Includes interest income and income related to research tax credits.
3. For the twelve months ended December 31, 2025, adjustments primarily include expenses related to Veracyte SAS impairment loss ($20.5M), Veracyte SAS investment review ($7.7M), the exclusion of unrealized loss related to Veracyte SAS deconsolidation ($6.7M), the restructuring and liquidation proceedings of Veracyte SAS ($3.8M), and other legal proceedings ($1.0M), partially offset by adjustments related to restructuring costs ($0.1M), vendor legal settlement ($2.8M), and the exclusion of unrealized gains associated with foreign exchange impacts on stock-based compensation and intercompany loans ($2.3M). For the twelve months ended December 31, 2024, adjustments primarily include expense related to restructuring costs associated with a reduction in our Biopharmaceutical and Other segment and with portfolio prioritization, expense related to Veracyte SAS site investment review, expense related to the impairment charge associated with HalioDx and the exclusion of unrealized losses associated with foreign exchange impacts on stock-based compensation and intercompany loans. For the twelve months ended December 31, 2023, adjustments primarily include expense related to the impairment charge associated with the nCounter license intangible assets ($34.9M), expense related to the impairment charge associated with HalioDx ($32.0M) and related to other impairment charges ($1.3M). For the twelve months ended December 31, 2022, adjustments primarily include expense related to the impairment charge associated with certain developed technology intangible assets ($3.3M) and related to restructuring costs ($0.5M).

Reconciliation of Non-GAAP Net Income, EPS and WASO

(Unaudited)
(In thousands of dollars)

Three Months Ended	Jun 30, 2025	Sep 30, 2025	Dec 31, 2025	Mar 31, 2026	Jun 30, 2026	Sep 30, 2026
GAAP Net Income (Loss)	**$ (980)**	**$ 19,137**	**$ 41,149**	**$ 28,707**	**$ 25,490**	**$ 31,503**
Amortization of intangible assets	3,288	3,329	3,329	3,286	3,163	3,687
Stock-based compensation expense	10,985	10,757	10,901	12,761	14,086	13,959
Acquisition related expenses (1)	(925)	166	(12,564)	(367)	(319)	1,453
Other adjustments (2)	22,147	8,138	1,590	(1,520)	2,712	3,231
Tax adjustments (3)	437	(565)	(1,590)	(753)	(802)	(11,971)
Non-GAAP Net Income	**$ 34,952**	**$ 40,962**	**$ 42,815**	**$ 42,114**	**$ 44,330**	**$ 41,862**
Diluted EPS, GAAP	$ (0.01)	$ 0.24	$ 0.51	$ 0.35	$ 0.31	$ 0.38
Amortization of intangible assets	0.04	0.04	0.04	0.04	0.04	0.04
Stock-based compensation expense	0.14	0.13	0.13	0.16	0.17	0.17
Acquisition related expenses (1)	(0.01)	-	(0.15)	-	-	0.02
Other adjustments (2)	0.28	0.10	0.02	(0.02)	0.03	0.04
Tax adjustments (3)	0.01	(0.01)	(0.02)	(0.01)	(0.01)	(0.14)
Rounding and impact of dilutive shares	(0.01)	0.01	-	-	-	-
Diluted EPS, non-GAAP	**$ 0.44**	**$ 0.51**	**$ 0.53**	**$ 0.52**	**$ 0.54**	**$ 0.51**
Diluted WASO, GAAP	78,391,502	79,691,703	81,387,089	81,313,588	82,059,442	82,783,915
Dilutive effect of equity awards (4)	1,057,711	-	-	-	-	-
Diluted WASO, non-GAAP	**79,449,213**	**79,691,703**	**81,387,089**	**81,313,588**	**82,059,442**	**82,783,915**

1. Includes transaction-related expenses as well as post-combination compensation expenses. For the three months ended September 30, 2026, adjustments consist primarily of transaction-related expenses associated with the acquisition activities ($1.9 million), partially offset by contingent consideration related to the NanoString transaction ($0.4 million). For the three months ended June 30, 2026, adjustments consist primarily of transaction-related expenses associated with contingent consideration related to the NanoString transaction ($0.3M). For the three months ended March 31, 2026, adjustments consist primarily of transaction-related expenses associated with contingent consideration related to the NanoString transaction ($0.4M). For the three months ended December 31, 2025, adjustments consist primarily of transaction-related expenses associated with contingent consideration related to NanoString ($0.7M) and contingent consideration associated with the acquisition of C2i Genomics ($11.9M). For the three months ended September 30, 2025, adjustments consist primarily of transaction-related expenses associated with contingent consideration related to NanoString and contingent consideration associated with the acquisition of C2i Genomics. For the three months ended June 30, 2025, adjustments consist primarily of transaction-related expenses associated with contingent consideration related to NanoString ($1.0M) partially offset by contingent consideration associated with the acquisition of C2i Genomics ($0.1M).
2. For the three months ended September 30, 2026, adjustments consist primarily of expenses related to legal proceedings ($3.2M). For the three months ended June 30, 2026, adjustments consist primarily of expenses related to the assessment of licensing and strategic investments ($1.3M), expenses related to legal proceedings ($1.0M), and expenses related to the liquidation proceedings of Veracyte SAS ($0.3M). For the three months ended March 31, 2026, adjustments primarily include impacts from the restructuring and liquidation proceedings of Veracyte SAS ($4.2M), partially offset by expenses related to the assessment of licensing and strategic investments ($1.7M), other legal proceedings ($0.6M) and losses related to asset disposition ($0.4M). For the three months ended December 31, 2025, adjustments primarily include expenses related to the restructuring and liquidation proceedings of Veracyte SAS ($1.4M) and other legal proceedings ($0.2M). For the three months ended September 30, 2025, adjustments primarily include expenses related to the exclusion of unrealized loss related to Veracyte SAS deconsolidation ($6.7M), the exclusion of unrealized loss associated with foreign exchange impact on stock-based compensation and intercompany loans ($1.3M), the restructuring and liquidation proceedings of Veracyte SAS ($2.4M), and other legal proceedings ($0.5M), partially offset by vendor legal settlement ($2.8M). For the three months ended June 30, 2025, adjustments primarily include expenses related to Veracyte SAS impairment loss ($20.5M) and the restructuring and liquidation proceedings of Veracyte SAS ($4.2M), partially offset by the exclusion of unrealized gains associated with foreign exchange impacts on stock-based compensation and intercompany loans ($2.5M).
3. Incremental non-GAAP tax expense reflects the tax impact of the non-GAAP adjustments listed.
4. In those periods in which GAAP net (loss) income is negative and non-GAAP net (loss) income is positive, non-GAAP diluted weighted average shares outstanding includes potentially dilutive common shares from equity awards as determined using the treasury stock method.
5. Some figures rounded for reporting purposes. Summed quarters may differ slightly from year-to-date figures presented due to rounding or use of weighted-averages when calculating earnings per share.

veracyte®

